KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis
about
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastasesTargeting SRC in mucinous ovarian carcinoma.KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma.Ras in cancer and developmental diseasesKRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitorsDifferent metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer.Review of histopathological and molecular prognostic features in colorectal cancerKras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian populationKRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implicationsKRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonistsAssociation between KRAS mutation and lung metastasis in advanced colorectal cancer.Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy.KRAS mutations and subtyping in colorectal cancer in Jordanian patients.Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastasesKRAS mutation in lung metastases from colorectal cancer: prognostic implications.Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximabEvidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy.RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.PAR-4 as a possible new target for pancreatic cancer therapy.Pathobiology of colorectal cancer hepatic metastases with an emphasis on prognostic factors.Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches.Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.New and potential clinical applications of KRAS as a cancer biomarker.KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.Pragmatic issues in biomarker evaluation for targeted therapies in cancer.Management of resectable colorectal lung metastases.Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.Tumour heterogeneity: principles and practical consequences.Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations†.Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA.Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
P2860
Q28088489-173F9B65-409B-4167-A297-992CF3DB48F8Q33638051-3013AD58-AEF7-48AA-A041-2B58D3D5B0A9Q34141770-BCB185FB-A857-4098-AAF3-C4D7BAB7EEA9Q34202697-FD2E0EB3-27D3-496A-B0AB-D4FCDB690638Q34295425-EB62EC1A-7B73-4353-9C00-D0DA8A44B620Q34372824-D2D72C95-2181-4095-83AB-FE60F42F4AF9Q34657323-47CAFE9A-1341-487F-8D3C-2541D4D1B4BEQ34661887-C8183BFD-D468-43A3-8A57-E7B850A2D884Q34727184-328B9D14-EBB4-43B4-8C11-3C6A52578819Q35069989-F5A2D8CD-3DFC-42D9-8DFA-604A52866555Q35098287-694A4FE4-7BB2-4C07-80D9-D0E0DE92CB87Q35128358-38C045DD-F06E-4658-9962-43289FDF06CCQ35223622-CA49DD72-E541-43FC-ABDE-152B94E8E857Q35459134-3C645FCB-A897-4728-9822-6DE61ECE7D33Q35677827-49DB6DCF-9FC0-4FF2-AA5D-B688931EAD1EQ35709696-85C64E01-09E7-41E0-8FB6-EA5DDCE6BFB7Q36086837-CFD77A48-2052-4E48-8EFC-F270FFF229EEQ36097103-78DFE721-D0AA-472E-B424-2D1430FBC1E9Q36424058-E11D1079-406D-4842-B165-40ED52A6FAD0Q36465989-FDC20ECB-2793-44D0-A08A-9349E0BA53CBQ36528345-EC896B5E-C0BC-47E7-8332-C5319B4F96DDQ37067203-BD2AF9AC-7D80-4AD2-B43D-52FC061E93D4Q37225348-277FF613-1032-4A9B-A4C7-ECF338CC1F24Q37375848-4D8B784E-1738-40EF-93C7-BDA8F33FDF18Q37709323-6470789D-42A5-483C-80D9-478FCA081C7AQ37738894-C19B732F-FEAE-4089-B614-00CFC5F5E0F2Q37821837-DB0A3743-7158-4C19-8163-0A62D16DB38CQ37899687-CD9DE1DE-A14B-4B06-AE2A-1B444709545BQ37951604-BD4B38D5-3DE2-4B54-B85A-427169B0D2B3Q38052918-5BEF3452-BB51-4F57-8C96-E4758732FDD9Q38089885-A557F533-58CF-4377-A541-68AED98DC890Q38136134-C90361E3-D7F5-4637-9DF4-D3C87A778D60Q38271031-EC1691A0-28B5-4715-99B9-ADEEACA70973Q38667176-1EE32C8C-3974-4802-814F-41510886B461Q38698206-7C6DBB69-5973-45BC-95A1-A8536D8041E1Q38842168-B7E902BC-CA00-422E-BD9C-3C945861A88BQ38967826-91D9F8AB-E491-4953-804D-FE200E311D7FQ39344296-E93E3C9A-B48D-484C-A515-0533E04BCC38Q39704299-27CD09CB-FF67-4B6E-A968-667E6BA7ADD9Q39722702-00F5CCEE-6D05-43A1-BEE1-1E42644A22D5
P2860
KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
KRAS mutations in primary colo ...... prediction of lung metastasis
@ast
KRAS mutations in primary colo ...... prediction of lung metastasis
@en
KRAS mutations in primary colo ...... prediction of lung metastasis.
@nl
type
label
KRAS mutations in primary colo ...... prediction of lung metastasis
@ast
KRAS mutations in primary colo ...... prediction of lung metastasis
@en
KRAS mutations in primary colo ...... prediction of lung metastasis.
@nl
prefLabel
KRAS mutations in primary colo ...... prediction of lung metastasis
@ast
KRAS mutations in primary colo ...... prediction of lung metastasis
@en
KRAS mutations in primary colo ...... prediction of lung metastasis.
@nl
P2093
P2860
P1433
P1476
KRAS mutations in primary colo ...... prediction of lung metastasis
@en
P2093
Cristina Aguayo
Enrique Casado
Jaime Feliu
Javier Larrauri
Javier de Castro Carpeño
Jorge Barriuso
Manuel Gonzalez-Barón
Miriam López-Gómez
Paloma Cejas
Rocío López
P2860
P356
10.1371/JOURNAL.PONE.0008199
P407
P577
2009-12-18T00:00:00Z